Citigroup
RARE icon

Citigroup’s Ultragenyx Pharmaceutical RARE Stock Holding History

Citigroup’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-15,700
Closed -$472K – 6389
2025
Q3 		$472K Buy
+15,700
New +$471K ﹤0.01% 3610
2025
Q2 		– Sell
-29,900
Closed -$1.08M – 5857
2025
Q1 		$1.08M Sell
29,900
-16,100
-35% -$670K ﹤0.01% 3195
2024
Q4 		$1.94M Buy
46,000
+30,000
+188% +$1.49M ﹤0.01% 2849
2024
Q3 		$889K Buy
+16,000
New +$815K ﹤0.01% 3351
2024
Q1 		– Sell
-74,500
Closed -$3.56M – 5815
2023
Q4 		$3.56M Buy
74,500
+54,300
+269% +$2.11M ﹤0.01% 1821
2023
Q3 		$720K Sell
20,200
-9,700
-32% -$384K ﹤0.01% 2778
2023
Q2 		$1.38M Sell
29,900
-25,000
-46% -$1.16M ﹤0.01% 2557
2023
Q1 		$2.2M Sell
54,900
-22,800
-29% -$978K ﹤0.01% 1954
2022
Q4 		$3.6M Buy
+77,700
New +$3.06M ﹤0.01% 1662
2020
Q2 		– Sell
-7,500
Closed -$333K – 7649
2020
Q1 		$333K Sell
7,500
-5,300
-41% -$275K ﹤0.01% 4247
2019
Q4 		$547K Buy
12,800
+7,600
+146% +$314K ﹤0.01% 4351
2019
Q3 		$222K Sell
5,200
-800
-13% -$43.5K ﹤0.01% 5064
2019
Q2 		$381K Buy
6,000
+700
+13% +$44.6K ﹤0.01% 4690
2019
Q1 		$368K Buy
5,300
+4,000
+308% +$229K ﹤0.01% 4508
2018
Q4 		$57K Sell
1,300
-2,900
-69% -$158K ﹤0.01% 6127
2018
Q3 		$321K Buy
4,200
+2,700
+180% +$220K ﹤0.01% 4765
2018
Q2 		$115K Sell
1,500
-2,000
-57% -$129K ﹤0.01% 5590
2018
Q1 		$178K Sell
3,500
-2,200
-39% -$111K ﹤0.01% 5083
2017
Q4 		$264K Buy
5,700
+3,600
+171% +$177K ﹤0.01% 4780
2017
Q3 		$112K Sell
2,100
-4,000
-66% -$237K ﹤0.01% 5471
2017
Q2 		$379K Sell
6,100
-2,500
-29% -$151K ﹤0.01% 4244
2017
Q1 		$583K Sell
8,600
-1,500
-15% -$114K ﹤0.01% 3734
2016
Q4 		$710K Buy
10,100
+9,500
+1,583% +$674K ﹤0.01% 4028
2016
Q3 		$43K Buy
+600
New +$38.3K ﹤0.01% 5763

Other funds holding RARE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Citigroup's RARE Position: Q2 2026 in Review

Citigroup reduced its Ultragenyx Pharmaceutical (RARE) stake by 5.3% in Q2 2026, selling an estimated $414K and leaving 298,785 shares worth $9.98M. The position accounts for ﹤0.01% of the portfolio, ranked #1622.

Citigroup first reported a position in RARE in Q1 2014 and has held it in 50 quarters since. 311 funds tracked by Wall St. Rank hold RARE as of Q2 2026.

  • Citigroup held 298,785 shares of Ultragenyx Pharmaceutical worth $9.98M as of Q2 2026.
  • Citigroup sold 16,655 Ultragenyx Pharmaceutical shares in Q2 2026, an estimated $414K.
  • Ultragenyx Pharmaceutical made up ﹤0.01% of Citigroup's portfolio in Q2 2026, its #1622 holding.
  • Citigroup first reported a position in Ultragenyx Pharmaceutical in Q1 2014 and has held it in 50 quarters since.
  • 311 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.